Peregrine Announces Opening of a New Study At the Stanford University, Stanford, CA
(Business Wire)...~~~ Cotara, Peregrine`s Tumor Necrosis Therapy (TNT) drug, is a radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out.......Cotara is currently being studied in a multi-center Phase II study for Brain cancer....- Apr 09 7:31 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010409/2064.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines